Search > Lung Cancer
184 Participants NeededMy employer runs this trial

Risvutatug Rezetecan + Ivonescimab for Lung Cancer

Recruiting at 3 trial locations
Age: 18+
Sex: Any
Trial Phase: Phase 1 & 2
Sponsor: GlaxoSmithKline
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This is an early-phase clinical study investigating a new combination treatment, Risvutatug rezetecan (Ris-Rez) given with ivonescimab for adults with advanced solid cancers. The study aims to determine:

* What dose(s) of Ris-Rez given with ivonescimab is safe and what are the side effects?

* How does the body handle the drug(s)?

* What dose of Ris-Rez given with ivonescimab may work best and can improve the treatment of cancer?

Are You a Good Fit for This Trial?

This trial is for adults (18+) with advanced lung cancer, including certain types of small cell and non-small cell lung cancers that have spread. Participants must be able to carry out daily activities, have at least one measurable tumor, good organ function, and a life expectancy of at least 3 months.

Inclusion Criteria

Has a life expectancy of ≥ 3 months with ability to complete at least 4 cycles of study intervention
My lung cancer type has been confirmed as squamous or non-squamous NSCLC.
I can provide a tumor sample for B7-H3 testing unless it's not medically possible.
See 9 more

Exclusion Criteria

History of allergy or hypersensitivity to Ris-Rez or its components, severe allergies, severe infusion-related reactions, or idiosyncrasy to recombinant humanized or mouse proteins
I do not have heart rhythm problems or a low heart pumping function.
I still have side effects from previous treatment that have not improved.
See 17 more

What Are the Treatments Tested in This Trial?

Interventions

  • Ivonescimab
  • Risvutatug rezetecan

Trial Overview

The study is testing the safety and best dose of two new drugs—Risvutatug rezetecan combined with ivonescimab—in people with advanced solid tumors. Researchers will monitor how the body processes these drugs and their effects on cancer.

How Is the Trial Designed?

2

Treatment groups

Experimental Treatment

Group I: Phase 2: Dose expansionExperimental Treatment2 Interventions
Group II: Phase 1: Dose escalationExperimental Treatment2 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

GlaxoSmithKline

Lead Sponsor

Trials
4,834
Recruited
8,389,000+
Headquarters
London, UK
Known For
Vaccines & Medicines
Top Products
**Advair (salmeterol, fluticasone propionate)**, **Shingrix (shingles vaccine)**, **Augmentin (amoxicillin/clavulanate potassium)**, **Ventolin (salbutamol sulfate)
Dame Emma Walmsley profile image

Dame Emma Walmsley

GlaxoSmithKline

Chief Executive Officer since 2017

MA in Classics and Modern Languages from Oxford University

Dr. Hal Barron profile image

Dr. Hal Barron

GlaxoSmithKline

Chief Medical Officer since 2018

MD from Harvard Medical School

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.